Immix Biopharma Insider Buying Signals Confidence in Oncology and IBD Pipeline
Insider RSU buy at Immix Biopharma signals confidence in its oncology and IBD pipeline; early-phase data, upcoming FDA reviews, and CEO stake suggest a potential upside for investors.
4 minutes to read